StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Additions Charged to Gross Sales by Year

Additions Charged to Gross Sales ($M)

Novartis Additions Charged to Gross Sales: $25,818M in FY2025, up 22.0% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
25,818
Period ended Dec 31, 2025
Change on a year earlier
+22.0%
21,157 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Novartis Form 20-F (0001114448-26-000004) ↗

Reported in Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdditions Charged to Gross Sales ($M)Year on yearSource
FY2025Dec 31, 202525,818+22.0%Novartis Form 20-F (0001114448-26-000004) ↗
FY2024Dec 31, 202421,157+18.9%Novartis Form 20-F (0001114448-26-000004) ↗
FY2023Dec 31, 202317,798+16.9%Novartis Form 20-F (0001114448-26-000004) ↗
FY2022Dec 31, 202215,231+16.4%Novartis Form 20-F (0001370368-25-000004) ↗
FY2021Dec 31, 202113,084-33.8%Novartis Form 20-F (0001370368-24-000004) ↗
FY2020Dec 31, 202019,773-1.1%Novartis Form 20-F/A (0001370368-23-000048) ↗
FY2019Dec 31, 201920,001+9.6%Novartis Form 20-F (0001370368-22-000010) ↗
FY2018Dec 31, 201818,248+2.7%Novartis Form 20-F (0001370368-21-000006) ↗
FY2017Dec 31, 201717,772+6.1%Novartis Form 20-F (0001370368-20-000003) ↗
FY2016Dec 31, 201616,758–Novartis Form 20-F (0001370368-19-000002) ↗

Cite this data

StockData. (2026). Novartis Additions Charged to Gross Sales ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/gtn-current-year-charge

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.